Skip to main content

Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis

    Basic Details
    Date Posted
    Friday, April 21, 2023
    Status
    Complete
    Medical Product
    sacubitril/valsartan
    Health Outcome(s)
    angioedema
    Description

    This analysis investigates the risk of angioedema in patients with heart failure associated with (1) sacubitril/valsartan (SV) use comparing those with prior angiotensin-converting enzyme inhibitors (ACEI) use and those with prior angiotensin II receptor blockers use (ARBs, excluding SV) use; (2) SV use comparing those with and without prior ACEI use; and (3) SV use comparing those with and without prior ARB use. This analysis follows up and expands upon the work conducted in the earlier Sentinel drug analysis, Angioedema following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis, which assessed different combinations of SV, ACEI and ARB new user cohorts.  

    The study period includes data from July 15, 2015 up to February 29, 2020. We distributed this request to five Sentinel Data Partners on January 18, 2022.